Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation
Ke Zhan, Shengtao Liao, Jinfang Li, Yang Bai, Lin Lv, Keqi Yu, Liewang Qiu, Chuanfei Li, Guodan Yuan, An Zhang, Zhechuan Mei
Abstract
Tamoxifen has been the standard adjuvant therapy for patients with breast cancer for several decades. Various recently completed adjuvant trials using aromatase inhibitors have shown the superiority of these agents over Tamoxifen or placebo, when used in post-menopausal women. The results from these trials present a challenging situation for practicing oncologists with regards to the choice, duration, sequence of therapy, follow-up and side-effects of aromatase inhibitors. Various management issues from a practical angle for oncologists are discussed for the effective use of these agents, with an evidence-based approach.